Androgen Receptor Polymorphism-Dependent Variation in Prostate-Specific Antigen Concentrations of European Men

    September 2014 in “ Cancer Epidemiology, Biomarkers & Prevention ”
    Magdalena Bentmar Holgersson, Aleksander Giwercman, Anders Bjartell, Frederick C. W. Wu, Ilpo Huhtaniemi, Terence W O'Neill, Neil Pendleton, Dirk Vanderschueren, Michael E. J. Lean, Thang S. Han, Joseph D. Finn, Krzysztof Kula, Gianni Forti, Felipe F. Casanueva, György Bártfai, Margus Punab, Yvonne Lundberg Giwercman
    Image
    Studysummary This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study examined the association between androgen receptor (AR) genetic variants and prostate-specific antigen (PSA) levels in 1,744 European men aged 40 to 79 without prostate cancer. It found that men carrying the A-allele of the single nucleotide polymorphism (SNP) rs1204038, which represented 16% of the cohort, had a 65% higher risk of having PSA levels above 3 ng/mL and an 87% higher risk of having PSA levels above 4 ng/mL compared to carriers of the G-allele. These men also had shorter CAG repeats in the AR gene, although CAG repeat length alone did not affect PSA levels. The study concluded that the A-allele of SNP rs1204038 is associated with higher PSA concentrations, which could lead to an increased likelihood of being referred for further prostate cancer examination, despite a lower history of prostate cancer diagnosis. The findings suggest that adjusting serum PSA levels for AR genotype could improve the clinical utility of PSA as a marker for prostate cancer screening.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results